Natco Pharma has announced the launch of the first generic version of Nexavar (Sorafenib) tablets in the US market on Wednesday.
The product will be launched by Hyderabad-based Natco Pharma’s commercial partner, Viatris, a global pharmaceutical company.
Sorafenib is prescribed for the treatment of unresectable hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC) and Differentiated Thyroid Carcinoma (DTC).
Nexavar registered sales of $ 69.7 million for the year ending December 2021 as per industry sales data. Nexavar is a registered trademark of Bayer Healthcare Pharmaceuticals Inc, according to a release.